Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283519910> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W4283519910 endingPage "S287" @default.
- W4283519910 startingPage "S287" @default.
- W4283519910 abstract "Drug price negotiation for Medicare is being considered by the United States Congress. The National Academy of Medicine recommends that such drug prices be value-based. One way to inform value-based drug prices is to cap prices at the level necessary to achieve a given cost-effectiveness threshold. Such prices, known as value-based prices (VBPs), are recorded in evidence reviews from the Institute for Clinical and Economic Review (ICER). The objective of this study is to estimate US national drug spending changes if drug prices were capped at ICER VBPs. We obtained drug- and indication-specific VBPs from ICER evidence reports from November 2007 to October 2020. We merged in drug-specific net sales (i.e., sales net of all rebates, discounts, and fees paid by the manufacturer) in 2019, as reported in manufacturer 10-Q financial filings collected by SSR Health. We calculated total net drug spending, as well as total drug spending after applying VBP caps of $100,000/quality-adjusted life-years (QALY) and $150,000/QALY for the drugs of interest. For drugs with multiple VBPs (due to multiple indications), we used the highest drug-specific VBP (base case), and lowest drug-specific VBP (sensitivity analysis). There were 54 drugs with manufacturer-reported net sales data in 2019 for a total of 81 indications. These drugs represented $96.3 billion in total net drug spending. In the base case, we found reductions in total net drug spending of $35.9 billion (37.2%) and $6.2 billion (6.5%) when we applied VBP caps of $100,000/QALY and $150,000/QALY, respectively. In the sensitivity analysis, we found reductions in total net drug spending of $47.9 billion (49.7%) and $28.4 billion (29.5%), when we applied VBP caps of $100,000/QALY and $150,000/QALY respectively. Applying VBP caps even for this small number of ICER-reviewed drugs could result in substantial US national drug savings." @default.
- W4283519910 created "2022-06-27" @default.
- W4283519910 creator A5001925291 @default.
- W4283519910 creator A5034154374 @default.
- W4283519910 creator A5066238395 @default.
- W4283519910 creator A5070915674 @default.
- W4283519910 date "2022-07-01" @default.
- W4283519910 modified "2023-10-16" @default.
- W4283519910 title "P1 Estimating US National Prescription Drug Savings from Applying Value-Based Price Caps" @default.
- W4283519910 doi "https://doi.org/10.1016/j.jval.2022.04.009" @default.
- W4283519910 hasPublicationYear "2022" @default.
- W4283519910 type Work @default.
- W4283519910 citedByCount "0" @default.
- W4283519910 crossrefType "journal-article" @default.
- W4283519910 hasAuthorship W4283519910A5001925291 @default.
- W4283519910 hasAuthorship W4283519910A5034154374 @default.
- W4283519910 hasAuthorship W4283519910A5066238395 @default.
- W4283519910 hasAuthorship W4283519910A5070915674 @default.
- W4283519910 hasBestOaLocation W42835199101 @default.
- W4283519910 hasConcept C10138342 @default.
- W4283519910 hasConcept C119857082 @default.
- W4283519910 hasConcept C144133560 @default.
- W4283519910 hasConcept C162118730 @default.
- W4283519910 hasConcept C162324750 @default.
- W4283519910 hasConcept C2426938 @default.
- W4283519910 hasConcept C2776291640 @default.
- W4283519910 hasConcept C2778858636 @default.
- W4283519910 hasConcept C2780035454 @default.
- W4283519910 hasConcept C2910862244 @default.
- W4283519910 hasConcept C41008148 @default.
- W4283519910 hasConcept C556758197 @default.
- W4283519910 hasConcept C71924100 @default.
- W4283519910 hasConcept C98274493 @default.
- W4283519910 hasConceptScore W4283519910C10138342 @default.
- W4283519910 hasConceptScore W4283519910C119857082 @default.
- W4283519910 hasConceptScore W4283519910C144133560 @default.
- W4283519910 hasConceptScore W4283519910C162118730 @default.
- W4283519910 hasConceptScore W4283519910C162324750 @default.
- W4283519910 hasConceptScore W4283519910C2426938 @default.
- W4283519910 hasConceptScore W4283519910C2776291640 @default.
- W4283519910 hasConceptScore W4283519910C2778858636 @default.
- W4283519910 hasConceptScore W4283519910C2780035454 @default.
- W4283519910 hasConceptScore W4283519910C2910862244 @default.
- W4283519910 hasConceptScore W4283519910C41008148 @default.
- W4283519910 hasConceptScore W4283519910C556758197 @default.
- W4283519910 hasConceptScore W4283519910C71924100 @default.
- W4283519910 hasConceptScore W4283519910C98274493 @default.
- W4283519910 hasIssue "7" @default.
- W4283519910 hasLocation W42835199101 @default.
- W4283519910 hasOpenAccess W4283519910 @default.
- W4283519910 hasPrimaryLocation W42835199101 @default.
- W4283519910 hasRelatedWork W2000427913 @default.
- W4283519910 hasRelatedWork W2113102977 @default.
- W4283519910 hasRelatedWork W2202693847 @default.
- W4283519910 hasRelatedWork W2417392779 @default.
- W4283519910 hasRelatedWork W2471354286 @default.
- W4283519910 hasRelatedWork W3122180183 @default.
- W4283519910 hasRelatedWork W3125702933 @default.
- W4283519910 hasRelatedWork W4301321525 @default.
- W4283519910 hasRelatedWork W2277923778 @default.
- W4283519910 hasRelatedWork W2910357933 @default.
- W4283519910 hasVolume "25" @default.
- W4283519910 isParatext "false" @default.
- W4283519910 isRetracted "false" @default.
- W4283519910 workType "article" @default.